Pediatrix Medical Q1 GAAP EPS $0.05 vs $0.17 YoY; revenue up slightly to $495M

Pediatrix Medical Group, Inc.

2024-Q1 EPS reported $0.05 revenue$495,101,000

Net revenue $495M vs $491M YoY; same-unit revenue up 2.3%.
Net income $4M down from $14.2M; GAAP EPS $0.05 vs $0.17.
Adjusted EPS $0.20 vs $0.23; Adjusted EBITDA $37M vs $40.1M.
FY 2024 Adjusted EBITDA guidance reaffirmed $200M-$220M.
Cash used in ops $122.6M; total debt $705M at quarter end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Pediatrix Medical Group, Inc. reported the three months ended March 31, 2024 results: revenue $495.1 million, net income $4.0 million, EPS $0.05 per diluted share. Guidance reaffirmed.

Period: the three months ended March 31, 2024
Revenue: $495.1 million
Net income: $4.0 million
EPS: $0.05 per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

ended March 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.20. For the 2024 first quarter, Pediatrix reported the following results: • Net revenue of $495 million; • Net income of $4 million; and • Adjusted EBITDA of $37 million. “Our first quarter operating results were in line with our expectations,” said James D. Swift, M.D., Chief

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Pediatrix Medical Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-053917

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.